Arbutus Biopharma (NASDAQ:ABUS) 주식

Arbutus Biopharma

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Future Pandemics

Health Care

Legal

ABUS

MRNA

수요일 4월 3일, Arbutus Biopharma(NASDAQ:ABUS)의 주식은 회사가 법정에서 Moderna Inc(NASDAQ:MRNA)에 대한 소송을 제기할 권한을 부여받은 후 20% 이상 급등했다.



What Happened: Arbutus는 첫 소송에서 Moderna에 대해 클레임을 제기하는데 성공했는 데, 이 소송의 내용은 Moderna가 개발한 코로나 백신의 기반이 된

아르부투스 주식, 모더나와의 코로나 백신 특허 쟁송을 앞두고 급등

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corp

News

Horace Mann Educators Board Authorizes New Share Repurchase Program Of Up To $50M

Morgan Stanley analyst James Faucette maintains i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) with a Equal-Weight and lowers the price target from $27 to $25.

Price Target

Analyst Ratings

IIIV

Morgan Stanley Maintains Equal-Weight on i3 Verticals, Lowers Price Target to $25

HC Wainwright &amp; Co. analyst Richard Cathcart reiterates Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) with a Buy and maintains $2 price target.

Reiteration

INUV

HC Wainwright & Co. Reiterates Buy on Inuvo, Maintains $2 Price Target

<a href="https://www.globenewswire.com/Tracker?data=m86_IPRyJRgdp_Y9V7q4SgFzwddOD8TXjMcognaxk9gA88eQWgY3SWvmb-kkOFMIRKKBI_fiL9gm6KVFUmu_jeqkCyFITbEFzoP_TSwQ9BzTO4VWRTAovWlj_RRmJvJyzqgNe9F6IJhvXy2Mq1hIQYSpEYn5qoWWEffkZxSesAxeVRjD8YD39siciszjqdvijZ9xfUsIRgcpd4piqK95k17790euS92Wo37JOSYbX9W8PUNb-4uBRk9FuZwA_UYiIvBdmzK_hInfhvdvyibp1ht2BNRD0VPpx78hMns5dmwlbxkgRKSa0r2uLrd2Ze9UAqsY72xkWdvMOu9MkuaDXaDtq0b2WtoU499fP9wUfhaOikrLmmXcXiodcxFx0j0Q9BoLSz2U4GmZ-2FFDTEPJQ==">BioRestorative Therapies, Inc</a>. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease ("cLDD") enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell &amp; Gene Therapy ("ISCT") 2025 Annual Meeting.
No serious adverse events (SAEs) were reported, and there was no dose (40X106 cells) limiting toxicity at 26-104 weeks.

BRTX

BioRestorative Therapies Presents Preliminary Phase 2 BRTX-100 Data At ISCT 2025 Annual Meeting

Morgan Stanley analyst Jorge Kuri upgrades XP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) from Equal-Weight to Overweight and raises the price target from $18 to $24.

Upgrades

Morgan Stanley Upgrades XP to Overweight, Raises Price Target to $24

Highlights
<ul>
<li>Tamboran Resource Corporation has entered into subscription agreements to issue approximately 3.1 million shares of Common Stock in a Private Investment in Public Equity (PIPE) to institutional investors at a price of US$17.74 per share, representing a 15% discount to the closing price on May 12, 2025. Tamboran expects to receive gross proceeds of approximately US$55.4 million, before deducting placement agent fees and other offering expenses.</li>
<li>The initial US$44.4 million of the PIPE is expected to close on Friday May 16, 2025, subject to the satisfaction of customary closing conditions. The closing of the remaining US$11.0 million is subject to approval by Tamboran's shareholders and the satisfaction of other customary closing conditions.</li>
<li>Following the completion of the PIPE, Tamboran expects to be fully funded to drill and complete the remaining three wells required to deliver first gas under the proposed ~40 MMcf/d (~19 MMcf/d net Tamboran) Shenandoah South (SS) Pilot Project. First gas is planned for mid-2026, subject to weather and customary regulatory approvals.</li>
<li>Flow testing of the SS-2H sidetrack (SS-2H ST1) well has commenced after a longer "soaking" period following analysis of wells across the Beetaloo Bain to date. The IP30 flow test is expected to be announced in June 2025 and testing is planned to continue for a full 90-days.</li>
<li>Having secured funding, Tamboran plans to drill three wells commencing in mid-2025 to supply gas to the proposed SS Pilot Project. Following the drilling, Tamboran will stimulate four wells (the SS-3H well and the three wells drilled in 2025) under a single campaign to maximize cost and operational efficiencies planned for late 2025/1H 2026, subject to JV approval.</li>
<li>One well is planned to be flow tested following the stimulation campaign, with the remaining wells being cased and "soaked" ahead of production in mid-2026.</li>
</ul>

Tamboran Resource Enters Into Subscription Agreements To Issue About 3.1M Shares In PIPE To Institutional Investors At US$17.74/Shr; Expects To Receive Gross Proceeds Of About US$55.4M

Whoopi Goldberg urged taxpayers to "help the schools out" during the April 11 live broadcast of "<a href="https://x.com/TheView/status/1910356665070649847?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1910356665070649847%7Ctwgr%5E1fe314f391c5c3f10599e60dc7b5e1c6a83b66dd%7Ctwcon%5Es1_&amp;ref_url=https%3A%2F%2Fwww.gbnews.com%2Fcelebrity%2Fwhoopi-goldberg-outrage-trump-taxes-americans-the-view">The View</a>."
The longtime co-host urged <a href="https://www.benzinga.com/news/25/02/43888952/americans-owe-a-record-1-21-trillion-in-credit-card-debt-expert-warns-theres-no-end-in-sight">Americans</a> to "suck it up" and pay higher taxes to support failing schools and public institutions, even as she acknowledged that many families are "struggling with everything on a day-to-day basis."
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
<h2 class="wp-block-heading">Goldberg's Comments Hit Amid Budget Cuts and Inflation Woes</h2>
Goldberg's remarks followed a discussion about the administration's 90-day pause on reciprocal tariffs, excluding China. As she put it on-air, "We cannot depend on [the administration]. This is us&#8230; when I say us, I mean all of us."
Her comments came just days before a Senate vote to extend the 2017 Trump tax cuts, adding fuel to an already tense national conversation.
Her appeal lands as public education systems across the country brace for funding setbacks. <a href="https://www.pewtrusts.org/en/research-and-analysis/articles/2025/01/13/lawmakers-face-budget-crunches-tough-decisions-to-close-expected-shortfalls">Pew Charitable Trusts</a> reported in January that schools are facing deficits now that pandemic-era federal funding has dried up.&nbsp;
Districts are also dealing with stagnant enrollment and increasing demands for services. Meanwhile, <a href="https://apnews.com/article/texas-school-vouchers-bill-passed-76c867ca3ec874ed7ae8b9ef19e3608c">the Associated Press</a> reported that Texas passed a $1 billion school voucher bill allowing public money to be used for private school tuition — a move critics argue will siphon funds from public schools.
Trending: <a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a>
Goldberg defended former President Joe Biden's economic record, suggesting that Trump "ruined" the economy he inherited. While <a href="https://www.pbs.org/newshour/economy/u-s-inflation-at-9-1-percent-a-record-high">inflation hit 9% in 2022</a> under Biden, the <a href="https://www.bls.gov/opub/ted/2025/consumer-prices-up-2-4-percent-from-march-2024-to-march-2025.htm">U.S. Bureau of Labor Statistics</a> reported that in March, inflation had eased, with the consumer price index rising just 2.4% year-over-year—the lowest rate in five years.
In Washington, the debate over <a href="https://www.benzinga.com/startups/25/02/43729940/trumps-tariffs-could-raise-taxes-by-1-trillion-kevin-oleary-calls-it-the-beginning-of-a-negotiation">tax</a> policy continues to intensify. On April 5, Senate Republicans narrowly passed a budget resolution aimed at extending the 2017 Trump tax cuts, setting the stage for future legislation to make the cuts permanent. This move would cost nearly <a href="https://bipartisanpolicy.org/blog/the-new-cost-for-2025-tax-cut-extensions-4-trillion/">$4.1 trillion over a decade</a>.&nbsp;
According to a December report by the <a href="https://www.americanprogress.org/article/progressive-principles-for-the-2025-tax-debate-having-no-deal-is-better-than-having-a-bad-deal/">Center for American Progress</a>, extending the 2017 tax cuts would overwhelmingly benefit high-income earners, further exacerbating income inequality.
Read Next:
<ul class="wp-block-list">
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
Image: Shutterstock

Personal Finance

Whoopi Goldberg Says Americans Must 'Suck It Up' On Taxes – 'You Gotta Help The Schools Out'

B of A Securities analyst Ken Hoexter maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Buy and lowers the price target from $272 to $270.

B of A Securities Maintains Buy on FedEx, Lowers Price Target to $270

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">213.6400</td>
<td align="right">1.170</td>
<td align="right">0.55</td>
<td>6.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">85.0208</td>
<td align="right">0.441</td>
<td align="right">0.52</td>
<td>26.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">228.6000</td>
<td align="right">0.900</td>
<td align="right">0.39</td>
<td>37.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">140.7600</td>
<td align="right">0.460</td>
<td align="right">0.32</td>
<td>2.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.7800</td>
<td align="right">0.130</td>
<td align="right">0.31</td>
<td>4.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.9000</td>
<td align="right">0.030</td>
<td align="right">0.05</td>
<td>199.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">86.5600</td>
<td align="right">0.040</td>
<td align="right">0.04</td>
<td>802</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">99.2200</td>
<td align="right">0.020</td>
<td align="right">0.02</td>
<td>801</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">134.22</td>
<td align="right">-1.74</td>
<td align="right">-1.28</td>
<td>35.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">79.58</td>
<td align="right">-0.18</td>
<td align="right">-0.23</td>
<td>4.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.87</td>
<td align="right">-0.16</td>
<td align="right">-0.20</td>
<td>29.6K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For May 13, 2025

Trading Halt: Halt status updated at 9:10:00 AM ET: Quotation Resumption: News and Resumption Times

B of A Securities analyst Jeffrey Spector upgrades CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) from Neutral to Buy and raises the price target from $44 to $50.

CUBE

B of A Securities Upgrades CubeSmart to Buy, Raises Price Target to $50

BWS Financial analyst Hamed Khorsand maintains Sable Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) with a Sell and maintains $6 price target.

BWS Financial Maintains Sell on Sable Offshore, Maintains $6 Price Target

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>). &#8220;The pipes are a great business here, they <a href="https://www.benzinga.com/quote/ET/earnings">really are,&#8221; he added</a>.
On the earnings front, Energy Transfer reported quarterly earnings of 36 cents per share which missed the analyst consensus estimate of 37 cents per share on May 6.
Cramer said he is ok with Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>).
Lending support to his choice, HC Wainwright &amp; Co. analyst Yi Chen, on Monday, maintained Harrow with a Buy and raised the price target from $57 to $60.
&#8220;I think it can bottom here,&#8221; Cramer said when asked about Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). &#8220;I think that there's a lot of good stuff that they have, so I would say keep it here.&#8221;
Pfizer, on April 29, posted quarterly earnings of 92 cents per share, beating market estimates of 67 cents per share. The company&#8217;s quarterly sales came in at $13.71 billion, missing expectations of $13.95 billion.
The &#8220;Mad Money&#8221; host recommended to own Kinsale Capital Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>), saying that it is a &#8220;very good&#8221; stock.
Supporting his view, the company, on April 24, posted better-than-expected first-quarter earnings.
&#8220;All the insurers are really terrific right now, and they have been good for some time,&#8221; Cramer said when asked about Manulife Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFC#NYSE">MFC</a>). &#8220;They're all making fortunes, so I'm not going to go against any one of them.&#8221;
Manulife Financial, on May 7, reported quarterly earnings 69 cents per share on sales of $1.49 billion.
When asked about Iron Mountain (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>), he said, &#8220;No, better places to be.&#8221;
Iron Mountain, on May 1, posted better-than-expected earnings for the first quarter.
Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) has been such a &#8220;poor performer, I can't have you do that,&#8221; Cramer said.
On the earnings front, Devon Energy, on May 6, posted weaker-than-expected quarterly earnings.
Price Action:
<ul class="wp-block-list">
<li>Energy Transfer shares gained 1.3% to settle at $17.44 on Monday.</li>
<li>Harrow shares rose 9.3% to close at $26.66 during the session.</li>
<li>Devon Energy shares gained 3.1% to settle at $33.55 on Monday.</li>
<li>Pfizer shares gained 3.6% to settle at $23.09 on Monday.</li>
<li>Kinsale Capital shares rose 0.6% to close at $456.81.</li>
<li>Manulife Financial shares gained 2.8% to settle at $31.60 on Monday.</li>
<li>Iron Mountain shares gained 0.9% to close at $97.94 during the session.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45347009/top-2-tech-stocks-that-may-crash-in-q2">Top 2 Tech Stocks That May Crash In Q2</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

Trading Ideas

HROW

KNSL

Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock

<a href="https://www.globenewswire.com/Tracker?data=6gEe-_5a1fK1zLGcZt6_fqRPf4Ifx3C5Hpy61RyqIoy3FhZ13rUcu-zB-pdLDmarDnwuYN4btalRHYeuwgXb1EreljVmL9Y5C-25wBDON6M=">Mullen Automotive, Inc.</a> (NASDAQ:<a href="https://www.globenewswire.com/Tracker?data=XZu9-py7y1BhYHBEDA8kQjdUW8yQdOqYXtrCHWBGLXXkVAEMSJ-AdDoZygsClVJDak10DT00SC-3Q78ENNTtZYBD1WhCRG07i9Zl7-UiLKS4cBSetiFkXieqD21yaAnC"> MULN</a>) ("Mullen" or the "Company"), an electric vehicle ("EV") manufacturer, announces today that it has executed a settlement agreement with GEM Yield Bahamas Limited and GEM Global Yield LLC SCS (together, "GEM").
<ul>
<li>On May 9, 2025, Company executed a settlement agreement with GEM Group.</li>
<li>Under terms of the settlement agreement, GEM has a 55-day due diligence period, subject to extension by GEM, to evaluate the transfer to GEM of the Mishawaka assets in complete satisfaction of the judgement.</li>
<li>All collection activities have been suspended for the duration of the due diligence period.</li>
<li>Mullen continues to build its business and expand its existing Tunica, Mississippi, manufacturing capabilities to meet near and long-term demands for its multiple product lines.</li>
</ul>
"After four years of litigation we have executed a settlement agreement which provides a path forward to a full resolution with GEM and puts this matter behind us," said David Michery, CEO and chairman of Mullen Automotive. "I look forward to a great rest of 2025 and continued growth thereafter."

MULN

Mullen Automotive Enters Settlement With GEM Yield Bahamas Limited And GEM Global Yield LLC SCS; Under Terms. GEM Has A 55-Day Due Diligence Perior To Evaluate Transfer To GEM Of The Mishawaka Assets In Complete Satisfaction Of The Judgement

<ul>
<li>The latest approval will help provide clearer echocardiogram images for cardiologists to diagnose heart conditions in pediatric patients</li>
<li>Optison is the only polyethylene glycol (PEG)-free ultrasound enhancing agent available in the U.S.</li>
</ul>

Biotech

General

GEHC

GE HealthCare Announces FDA Approval For Optison Ultrasound Enhancing Agent

Interlink Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINK#NASDAQ">LINK</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.66 million which missed the analyst consensus estimate of $2.72 million by 1.99 percent. This is a 14.72 percent decrease over sales of $3.12 million the same period last year.

Earnings

Earnings Misses

LINK

Interlink Electronics Q1 EPS $(0.09) Misses $(0.07) Estimate, Sales $2.66M Miss $2.72M Estimate

B of A Securities analyst Conor Fitzpatrick initiates coverage on Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) with a Buy rating and announces Price Target of $15.

Initiation

CLMT

B of A Securities Initiates Coverage On Calumet with Buy Rating, Announces Price Target of $15

AMD Launches EPYC 4005 Series Processors

NEGG

Newegg Commerce Announces Exclusive Availability Of AMD EPYC 4005 Series Processors In North America Retail Launch

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Kelly Shi initiated coverage on Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy rating and announced a price target of $105. Insmed shares closed at $67.75 on Monday. <a href="https://www.benzinga.com/quote/INSM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Edward DeArias initiated coverage on Black Hills Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKH#NYSE">BKH</a>) with an Outperform rating and announced a price target of $68. Black Hills shares closed at $58.07 on Monday. <a href="https://www.benzinga.com/quote/BKH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Edward DeArias initiated coverage on Evergy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVRG#NASDAQ">EVRG</a>) with an Outperform rating and announced a price target of $75. Evergy shares closed at $65.35 on Monday. <a href="https://www.benzinga.com/quote/EVRG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Edward DeArias initiated coverage on Portland General Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Market Perform rating and announced a price target of $46. Portland Gen Electric shares closed at $42.62 on Monday. <a href="https://www.benzinga.com/quote/POR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Edward DeArias initiated coverage on Pinnacle West Capital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) with a Market Perform rating and announced a price target of $95. Pinnacle West Capital shares closed at $90.07 on Monday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying INSM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145-1024x601.png" alt="" class="wp-image-913464" style="width:593px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13090353/image-145.png 1076w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Markets

EVRG

INSM

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Press Releases

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus Provides 2025 Corporate and Financial Update

Management

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Comments

Arbutus Biopharma

뉴스

파트너 / 기고자

벤징가 글로벌